Compare Stocks: KYTX, NTLA, STOK, and TSHA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KYTX Kyverna Therapeutics	$6.84 +0.3%	$7.78	$5.30 ▼ $13.67	$422.99M	1.98	922,111 shs	826,210 shs
NTLA Intellia Therapeutics	$12.03 +5.3%	$11.99	$7.95 ▼ $28.25	$1.69B	1.82	5.10 million shs	5.01 million shs
STOK Stoke Therapeutics	$25.88 +1.5%	$30.12	$20.32 ▼ $40.22	$1.67B	1.23	774,989 shs	849,151 shs
TSHA Taysha Gene Therapies	$4.99	$5.69	$3.10 ▼ $7.30	$1.63B	1.19	2.95 million shs	5.26 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KYTX Kyverna Therapeutics	+0.15%	-4.21%	-18.52%	-23.46%	+11.80%
NTLA Intellia Therapeutics	-2.81%	-6.55%	-11.27%	-32.51%	-29.98%
STOK Stoke Therapeutics	+2.82%	-9.09%	-19.35%	-22.07%	+5.63%
TSHA Taysha Gene Therapies	+6.85%	-0.99%	-13.52%	-26.73%	+53.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KYTX Kyverna Therapeutics	$6.84 +0.3%	$7.78	$5.30 ▼ $13.67	$422.99M	1.98	922,111 shs	826,210 shs
NTLA Intellia Therapeutics	$12.03 +5.3%	$11.99	$7.95 ▼ $28.25	$1.69B	1.82	5.10 million shs	5.01 million shs
STOK Stoke Therapeutics	$25.88 +1.5%	$30.12	$20.32 ▼ $40.22	$1.67B	1.23	774,989 shs	849,151 shs
TSHA Taysha Gene Therapies	$4.99	$5.69	$3.10 ▼ $7.30	$1.63B	1.19	2.95 million shs	5.26 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KYTX Kyverna Therapeutics	+0.15%	-4.21%	-18.52%	-23.46%	+11.80%
NTLA Intellia Therapeutics	-2.81%	-6.55%	-11.27%	-32.51%	-29.98%
STOK Stoke Therapeutics	+2.82%	-9.09%	-19.35%	-22.07%	+5.63%
TSHA Taysha Gene Therapies	+6.85%	-0.99%	-13.52%	-26.73%	+53.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KYTX Kyverna Therapeutics	2.86	Moderate Buy	$29.00	323.98% Upside
NTLA Intellia Therapeutics	2.35	Hold	$20.98	74.38% Upside
STOK Stoke Therapeutics	2.82	Moderate Buy	$44.25	70.98% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$12.77	155.90% Upside

Current Analyst Ratings Breakdown

Latest KYTX, NTLA, STOK, and TSHA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	KYTX Kyverna Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$25.00
9/25/2026	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/25/2026	KYTX Kyverna Therapeutics	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/23/2026	KYTX Kyverna Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/21/2026	KYTX Kyverna Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/21/2026	TSHA Taysha Gene Therapies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/17/2026	TSHA Taysha Gene Therapies	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/10/2026	STOK Stoke Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/9/2026	NTLA Intellia Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$30.00
9/9/2026	NTLA Intellia Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$12.00 ➝ $13.00
9/9/2026	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00

(Data available from 9/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	$3.85 per share	N/A
NTLA Intellia Therapeutics	$67.67M	24.91	N/A	N/A	$5.80 per share	2.07
STOK Stoke Therapeutics	$184.42M	9.06	N/A	N/A	$6.17 per share	4.19
TSHA Taysha Gene Therapies	$9.77M	166.42	N/A	N/A	$0.90 per share	5.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KYTX Kyverna Therapeutics	-$161.31M	-$2.94	N/A	N/A	N/A	N/A	-81.92%	-63.74%	11/11/2026 (Estimated)
NTLA Intellia Therapeutics	-$412.69M	-$3.36	N/A	N/A	N/A	-672.16%	-57.79%	-47.29%	11/5/2026 (Estimated)
STOK Stoke Therapeutics	-$6.89M	-$3.34	N/A	N/A	N/A	-753.60%	-59.36%	-51.46%	11/3/2026 (Estimated)
TSHA Taysha Gene Therapies	-$109M	-$0.42	N/A	N/A	N/A	N/A	-56.19%	-41.84%	11/3/2026 (Estimated)

Latest KYTX, NTLA, STOK, and TSHA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	KYTX Kyverna Therapeutics	-$0.6783	-$0.63	+$0.0483	-$0.63	N/A	N/A
8/11/2026	Q2 2026	TSHA Taysha Gene Therapies	-$0.1133	-$0.13	-$0.0167	-$0.13	$0.68 million	N/A
8/6/2026	Q2 2026	NTLA Intellia Therapeutics	-$0.7993	-$0.80	-$0.0007	-$0.80	$12.98 million	$7.66 million
8/3/2026	Q2 2026	STOK Stoke Therapeutics	-$0.7950	-$0.93	-$0.1350	-$0.93	$4.89 million	$9.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KYTX Kyverna Therapeutics	0.15	9.06	9.06
NTLA Intellia Therapeutics	N/A	6.65	6.65
STOK Stoke Therapeutics	N/A	7.69	7.69
TSHA Taysha Gene Therapies	0.13	17.76	17.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KYTX Kyverna Therapeutics	18.08%
NTLA Intellia Therapeutics	88.77%
STOK Stoke Therapeutics	N/A
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
KYTX Kyverna Therapeutics	17.60%
NTLA Intellia Therapeutics	3.50%
STOK Stoke Therapeutics	9.60%
TSHA Taysha Gene Therapies	3.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KYTX Kyverna Therapeutics	149	61.84 million	50.96 million	Optionable
NTLA Intellia Therapeutics	377	140.13 million	135.22 million	Optionable
STOK Stoke Therapeutics	170	64.53 million	58.33 million	Optionable
TSHA Taysha Gene Therapies	99	325.83 million	314.50 million	Optionable

KYTX, NTLA, STOK, and TSHA Headlines

Recent News About These Companies

Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 5.7% - Here's What Happened

September 28 at 3:59 PM | marketbeat.com

Wolfe Research Initiates Coverage on Taysha Gene Therapies (NASDAQ:TSHA)

September 19, 2026 | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Earns Outperform Rating from Analysts at Wolfe Research

September 17, 2026 | marketbeat.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Buy" from Analysts

September 12, 2026 | marketbeat.com

Taysha Gene Therapies: A Bull Case That Does Not Require The Fastest Approval

September 11, 2026 | seekingalpha.com

These 3 Risky Stocks Could Be Sitting on 100% Upside (TSHA)

...

September 7, 2026 | marketbeat.com

Wellington Management Group LLP Acquires 3,349,244 Shares of Taysha Gene Therapies, Inc. $TSHA

September 6, 2026 | marketbeat.com

Bank of New York Mellon Corp Purchases New Position in Taysha Gene Therapies, Inc. $TSHA

September 6, 2026 | marketbeat.com

Seven Fleet Capital Management LP Has $9.94 Million Holdings in Taysha Gene Therapies, Inc. $TSHA

September 5, 2026 | marketbeat.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 4, 2026 | globenewswire.com

Taysha Gene Therapies Earnings Call Highlights Pivotal Progress

August 23, 2026 | tipranks.com

Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call

August 18, 2026 | finance.yahoo.com

Wells Fargo Issues a Buy Rating on Taysha Gene Therapies (TSHA)

August 14, 2026 | theglobeandmail.com

Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger

August 13, 2026 | finance.yahoo.com

Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026 | finanznachrichten.de

Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ...

August 12, 2026 | finance.yahoo.com

Taysha outlines REVEAL 6-month interim analysis and FDA feedback in H1 2027 while targeting PPQ completion in Q4 2026

August 12, 2026 | seekingalpha.com

Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript

August 11, 2026 | seekingalpha.com

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11, 2026 | globenewswire.com

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

August 4, 2026 | globenewswire.com

Taysha Taps Catalent for Potential Commercial Manufacturing of TSHA-102

August 3, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KYTX, NTLA, STOK, and TSHA Company Descriptions

Kyverna Therapeutics NASDAQ:KYTX

$6.84 +0.02 (+0.29%)

Closing price 04:00 PM Eastern

Extended Trading

$6.84 0.00 (-0.07%)

As of 07:41 PM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Intellia Therapeutics NASDAQ:NTLA

$12.03 +0.61 (+5.34%)

Closing price 04:00 PM Eastern

Extended Trading

$11.99 -0.04 (-0.33%)

As of 07:56 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Stoke Therapeutics NASDAQ:STOK

$25.88 +0.38 (+1.49%)

Closing price 04:00 PM Eastern

Extended Trading

$25.88 0.00 (-0.02%)

As of 07:30 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Taysha Gene Therapies NASDAQ:TSHA

$4.99 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$5.10 +0.11 (+2.20%)

As of 07:30 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KYTX, NTLA, STOK, and TSHA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KYTX, NTLA, STOK, and TSHA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KYTX, NTLA, STOK, and TSHA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KYTX, NTLA, STOK, and TSHA Company Descriptions

Kyverna Therapeutics NASDAQ:KYTX

Intellia Therapeutics NASDAQ:NTLA

Stoke Therapeutics NASDAQ:STOK

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KYTX, NTLA, STOK, and TSHA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KYTX, NTLA, STOK, and TSHA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KYTX, NTLA, STOK, and TSHA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KYTX, NTLA, STOK, and TSHA Company Descriptions

Kyverna Therapeutics NASDAQ:KYTX

Intellia Therapeutics NASDAQ:NTLA

Stoke Therapeutics NASDAQ:STOK

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools